• Neoimmunetech will hold investor relations meetings in Seoul’s Yeouido district on Nov. 4-5, 2026, for domestic analysts and institutional investors.
• Presentations and Q&A will cover research and development progress, technology licensing and the Endari business.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neoimmunetech Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261030900662), on October 30, 2026, and is solely responsible for the information contained therein.